In this episode, listen to Stephanie L. Graff, MD, FACP, FASCO; and Laura M. Spring, MD, share their clinical insights and takeaways regarding the current treatment landscape for first-line treatment of patients with HER2-positive metastatic breast cancer including: Data from multicenter, single-arm, phase IIIb/IV DESTINY-Breast12 evaluating trastuzumab deruxtecan (T-DXd) in patients with advanced HER2-positive metastatic breast cancer and 2 or fewer previous therapies Treatment sequencing and preferred treatment options in patients with brain metastases Results from phase III PATINA trial of trastuzumab, pertuzumab, plus endocrine therapy with or without palbociclib in hormone-receptor positive/HER2-positive metastatic breast cancer Thoughts on the use of T-DXd earlier in the treatment paradigm in light of recent results from the PATINA trial and highly anticipated results from the DESTINY-Breast09 trial Program faculty: Stephanie L. Graff, MD, FACP, FASCO Director of Breast Oncology, Brown University Health Co-Lead, Breast Cancer Translational Disease Research Group Legorreta Cancer Center at Brown University Associate Professor of Medicine Warren Alpert Medical School of Brown University Providence, Rhode Island Laura M. Spring, MD Breast Medical Oncologist Mass General Hospital Cancer Center Harvard Medical School Boston, Massachusetts Resources: To access the patient cases associated with this podcast discussion, please visit the program page and register for an upcoming webinar on this topic . Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
